Back to results
US 2024/0182979 A1Published application
Cancer biomarkers
AssigneeMyriad Genetics, Inc.
InventorsSteven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
Life of this patent
Estimating the term…
Abstract
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Claims12
A method for classifying prostate cancer in a patient, the method comprising:
- (a) extracting RNA from a sample from a patient with prostate cancer and reverse transcribing the RNA to cDNA;
- (b) amplifying the cDNA of a set of 10-30 marker genes comprising NUSAP1 and UBE2C;
- (c) detecting an expression level for each gene in the set of marker genes;
- (d) analyzing the expression levels of the set of marker genes by combining the expression levels to yield a combined score;
- and
- (e) classifying the tumor as responsive to a therapy if the combined score exceeds a threshold index value, or
- classifying the tumor as nonresponsive to a therapy if the combined score does not exceed the threshold index value,
- wherein the therapy comprises one or more of hormonal therapy, chemotherapy, radiation therapy, and surgery to excise tumor.
5 more elements
A method of analyzing a tumor sample, comprising:
- (a) obtaining a tumor sample from a patient with prostate cancer;
- (b) extracting RNA from the sample and reverse transcribing the RNA to cDNA;
- (c) amplifying the cDNA of a set of marker genes consisting of 10-30 marker genes comprising at least NUSAP1 and UBE2C;
- (d) determining the expression levels of the set of marker genes.
1 more element
Dependencies are inferred from the claim text.